Click here for slides on this topic


Incretin effect

The observation that oral glucose administration results in greater insulin secretory response than the same glucose amount administered intravenously.


The following content matched the glossary term: Incretin effect

NDEI.org Expert Commentary on EUREXA Trial Burton Sobel, MD

Top

NDEI.org expert commentary on European Exenatide (EUREXA) trial from Burton Sobel, MD

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

NDEI.org Expert Commentary Diabetes Monotherapy DURATION -4 Vivian Fonseca

Top

Expert commentary on diabetes monotherapy in DURATION-4 from Vivian Fonseca, MD

Clinical Insights in Diabetes Newsletter Archive

Top

Clinical Insights® in Diabetes Newsletter Archive

Glucagon-like peptide analogues for type 2 diabetes mellitus

Top

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD006423. Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes that mimic the endogenous hormone glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation in response to ingested nutrients.

Management of type 2 diabetes: new and future developments in treatment

Top

Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378(9786):182-97. The increasing prevalence, variable pathogenesis, progressive natural history, and complications of type 2 diabetes emphasise the urgent need for new treatment strategies.

Efficacy & Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared w/ Exenatide Twice Daily & Sitagliptin in Type 2 Diabetes Mellitus

Top

Pinelli NR, Hurren KM. Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis (July/August). Ann Pharmacother. 2011 Jul 5. [Epub ahead of print]. Long-acting glucagon-like peptide-1 receptor agonists (LA-GLP-1RAs) may deliver additional therapeutic benefits over other available incretin-based therapies.

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy

Top

Dicembrini I, Pala L, Rotella CM. From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy. Exp Diabetes Res. 2011;2011:898913. Epub 2011 Jun 23. Promoting long-term adherence to lifestyle modification and choice of antidiabetic agent with low hypoglycemia risk profile and positive weight profile could be the most effective strategy in achieving sustained glycemic control and in reducing comorbidities.

Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm

Top

Unger J. Clinical efficacy of GLP 1 agonists and their place in the diabetes treatment algorithm. J Am Osteopath Assoc. 2011;111(2 Suppl 1):eS2-9. Incretin-based therapies (subcutaneously administered glucagon-like peptide-1 [GLP-1] agonists and oral dipeptidyl peptidase-4 inhibitors) represent a new mechanism of action with which to target the adverse effects of type 2 diabetes mellitus.

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin

Top

Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009;25(8):1963-1972. Linagliptin (BI 1356) is a novel, orally available inhibitor of dipeptidyl peptidase-4 (DPP-4).

1 2 Next 

Slide Library Results

Search Results for: Incretin effect Slides Found: 1
GLP-1 Release Is Reduced in Type 2 Diabetes